Anna Maria Dworakowska

Dr. Anna Maria Dworakowska

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2024 in Healthcare
Verified
Journal Article
Open access
PDF file
JSJulia Siebielec
Julia Siebielec
Michal OrdakMichal Ordak
Michal Ordak
AOAgata Oskroba
Agata Oskroba
ADAnna Maria Dworakowska
Anna Maria Dworakowska
MBMagdalena Bujalska-Zadrozny
Magdalena Bujalska-Zadrozny
Background/Objectives: The use of artificial intelligence (AI) in education is dynamically growing, and models such as ChatGPT show potential in enhancing medical education. In Poland, to obtain a medical diploma, candidates must pass the Medical Final Examination, which consists of 200 questions with one correct answer per question, is administered in Polish, and assesses students’ comprehensive medical knowledge and readiness for clinical practice. The aim of this study was to determine how ChatGPT-3.5 handles questions included in this exam. Methods: This study considered 980 questions from five examination sessions of the Medical Final Examination conducted by the Medical Examination Center in the years 2022–2024. The analysis included the field of medicine, the difficulty index of the questions, and their type, namely theoretical versus case-study questions. Results: The average correct answer rate achieved by ChatGPT for the five examination sessions hovered around 60% and was lower (p < 0.001) than the average score achieved by the examinees. The lowest percentage of correct answers was in hematology (42.1%), while the highest was in endocrinology (78.6%). The difficulty index of the questions showed a statistically significant correlation with the correctness of the answers (p = 0.04). Questions for which ChatGPT-3.5 provided incorrect answers had a lower (p < 0.001) percentage of correct responses. The type of questions analyzed did not significantly affect the correctness of the answers (p = 0.46). Conclusions: This study indicates that ChatGPT-3.5 can be an effective tool for assisting in passing the final medical exam, but the results should be interpreted cautiously. It is recommended to further verify the correctness of the answers using various AI tools.

11 April 2018 in Public Health Nutrition
Verified
Journal Article
Closed access
PDF file
MMMagdalena Makarewicz-Wujec
Magdalena Makarewicz-Wujec
ADAnna Maria Dworakowska
Anna Maria Dworakowska
MKMałgorzata Kozłowska-Wojciechowska
Małgorzata Kozłowska-Wojciechowska
To present and discuss results of the most recent studies pertaining to the effects of consumption of different types of fatty acids on the risk of CVD. The aim was also an attempt to answer the question of whether a revision of the current recommendations is necessary. A review of prospective cohort studies, systematic reviews and meta-analyses published in 2014–2017 on the effects of SFA and trans-fatty acid (TFA) intakes as well as various models of their replacement in the diet on CVD risk. Results of the new large prospective cohort studies pertaining to the effect of SFA consumption on CVD risk are contradictory. Similarly, the recent meta-analyses of clinical trials related to the effects of SFA substitution on CVD risk provided extremely different results, which is related to the application of different inclusion and exclusion criteria. Differences in results of randomised controlled trials may be caused by different methodologies of dietary parameter changes, varying duration of studies, as well as the time at which they were carried out. It is extremely difficult to extrapolate results of recent studies to contemporary recommendations. It seems that there is a need for properly randomised studies on large groups, with good control of dietary and non-dietary parameters, which account for not only the sum of SFA and TFA, but also their source. Only such studies will allow for full evaluation of an effect of substituting SFA and TFA on cardiovascular risk.

5 February 2019 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
ALAgnieszka Lisowska
Agnieszka Lisowska
MMMagdalena Makarewicz-Wujec
Magdalena Makarewicz-Wujec
ADAnna Maria Dworakowska
Anna Maria Dworakowska
MKMałgorzata Kozłowska‐Wojciechowska
Małgorzata Kozłowska‐Wojciechowska
What is known and objective Myocardial infarction (MI) in young adults accounts for up to 10% of all cases. Regarding life expectancy and professional activity, it is extremely important to restore and maintain young patients’ full performance. Therefore, secondary prevention is especially vital in this group of patients. The paper focuses on the analysis of pharmacotherapy in young MI patients in Poland, assessing disparities between the European Society of Cardiology guidelines and clinical practice, and regional differences among the provinces. Methods The analysis was conducted using the data from a nationwide, observational, multicentre, prospective study—the Polish Registry of Acute Coronary Syndromes (PL‐ACS). The data were collected from patients ≤45 years old with MI who were hospitalized in the period 2010‐2014. Results and discussion A retrospective study included 6367 MI patients. They constituted 3.9% of all the patients with MI in Poland. Despite the fact that during hospitalization regional differences were observed in case of acetylsalicylic acid (range 70.3%‐93.8%), β‐blockers (range 50.0%‐79.6%), statins (range 53.4%‐85.7%) and angiotensin‐converting enzyme inhibitors (range 46.9%‐75.0%), the majority of patients received the drugs according to the guidelines. Regional differences found at discharge also regarded those medications, but the range of observed variations was smaller. On average, three‐quarter of patients received guideline‐recommended medications. Still, in some provinces, almost a quarter of patients were administered those medications only at discharge. What is new and conclusion In the study population, there were significant differences between the provinces regarding pharmacotherapy during hospitalization, which concerned major groups of medications. However, pharmacotherapy indicated at discharge revealed fewer regional differences and adhered to guideline recommendations to a greater extent. Nevertheless, there is still some room for improvement, especially with regard to pharmacotherapy during hospitalization.

8 January 2019 in European Geriatric Medicine
Verified
Journal Article
Closed access
PDF file
ADAnna Maria Dworakowska
Anna Maria Dworakowska
AAAdrianna Aniszewska
Adrianna Aniszewska
MKMałgorzata Kozłowska-Wojciechowska
Małgorzata Kozłowska-Wojciechowska

17 August 2026 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
EKEwa Kuczwalska
Ewa Kuczwalska
ADAnna Maria Dworakowska
Anna Maria Dworakowska
MSMagdalena Skarżyńska
Magdalena Skarżyńska
MBMagdalena Bujalska-Zadrożny
Magdalena Bujalska-Zadrożny
Introduction: Herpes zoster (HZ) remains an important cause of morbidity among older adults despite the availability of effective vaccines. Recommendations from healthcare professionals are among the strongest determinants of adult vaccination uptake, and community pharmacists are increasingly involved in vaccination recommendations. Objectives: To systematically review and critically appraise the evidence on the effectiveness of pharmacist-delivered recommendation strategies in increasing confirmed HZ vaccination uptake and recombinant zoster vaccine (RZV) series completion. Patients and methods: PubMed, Embase, and the Cochrane Library were searched from database inception to October 14, 2025. Studies evaluating pharmacist-delivered recommendation interventions aimed at increasing HZ vaccination were included if they reported quantitative outcomes for confirmed vaccination uptake or RZV series completion. Data on study characteristics, interventions, and vaccination outcomes were extracted. Risk of bias was assessed using RoB 2 and ROBINS-I. Results: Nine studies met the eligibility criteria for the primary synthesis of confirmed vaccination outcomes. Eight evaluated ZVL (Zostavax), whereas only one specifically assessed RZV (Shingrix) series completion. Seven studies were conducted in the United States and used predominantly non-randomized designs. Settings ranged from single community pharmacies to networks of 159 pharmacies. Positive effects on confirmed HZ vaccination uptake or RZV series completion were reported in five studies. The strongest evidence came from a cluster randomized controlled trial involving 16 pharmacies, in which automated telephone recommendations increased vaccination rates from 0.72 to 2.60% (OR 3.69; 95% CI 2.64–5.15). Additional positive findings were observed for personalized outreach and pharmacist telephone follow-up aimed at improving RZV series completion. Three studies reported no improvement or decreased HZ vaccination rates. The overall certainty of evidence was limited by methodological weaknesses: six of eight non-randomized studies were rated as having serious risk of bias, and only one randomized trial was available. Conclusion: Pharmacist-delivered recommendation strategies may improve HZ vaccination uptake and RZV series completion, particularly when implemented through proactive patient outreach. However, the current evidence base remains limited by the predominance of non-randomized studies and substantial risk of bias. Well-designed randomized and quasi-experimental studies are needed to determine the independent effectiveness of pharmacist-delivered vaccination recommendations.

Verified
Journal Article
Open access
PDF file
ADAnna Maria Dworakowska
Anna Maria Dworakowska
Jolanta MałyszkoJolanta Małyszko
Jolanta Małyszko
MBMagdalena Bujalska-Zadrozny
Magdalena Bujalska-Zadrozny
Appropriate dose adjustment of renally eliminated medicines is central to safe pharmacotherapy in patients with chronic kidney disease; yet, in European primary care, it is systematically undermined not by lack of knowledge, but by structural misalignment between laboratory reporting, regulatory product information, and clinical guidelines. This Perspective argues that the core barrier to optimal renal dose adjustment is a mismatch between routinely reported indexed eGFR and dosing requirements based on absolute renal function, compounded by persistent regulatory reliance on the Cockcroft–Gault equation despite its known limitations. We show how these structural inconsistencies, together with patient-related factors such as frailty, ageing, and body size, generate uncertainty at the point of prescribing and contribute to persistent variability in dosing decisions. To address this challenge, we propose a structured, context-aware renal dosing framework designed for routine primary care. The framework integrates regulatory guidance, multiple methods of renal function estimation, and patient-specific modifiers into a stepwise decision process. Clinical vignettes illustrate how divergent renal function estimates and regulatory requirements can lead to different dosing decisions in everyday practice. By reframing renal dose adjustment as a context-driven clinical process rather than a purely equation-based task, this Perspective highlights the need for regulatory alignment and pragmatic decision tools to improve prescribing quality in patients with chronic kidney disease.